Buenos Aires, Argentina – 13 April 2018
Argentina has approved the paediatric indication of a drug used for treatment of Chagas disease, benznidazole, which will now be available in 12.5 mg pills, the dose required to treat children under the age of 2. The indication was approved by the Argentinian National Administration for Drugs, Food, and Medical Technologies (ANMAT).
25-26 June 2018
Ivan Scandale, Senior Project Manager, Discovery – presentation on the filarial research landscape
Eric Stobbaerts, International Development Director – presentation on access to Chagas treatments in Latin America
Healio [8 April 2018]
“International partnership invests $15.5 million to combat neglected tropical diseases, TB, malaria”
31 May – 2 June 2018
Sergio Sosa-Estani, Head of Chagas, DNDi Latin America – session on etiological treatment on chronic phase of Chagas disease
24-26 May 2018
Jayme Fernandes, Senior CRA, DNDi Latin America – presentation on innovation in the field of Chagas and leishmaniasis treatments
23-25 May 2018
Poster on the mechanism of action of an experimental drug against Chagas disease
The Japanese pharmaceutical company Astellas Pharma Inc. is the eighth pharmaceutical company to join the Neglected Tropical Diseases Drug Discovery Booster, a global consortium launched in 2015 by DNDi to speed up the process and cut the cost of finding new treatments for leishmaniasis and Chagas disease.
Daiichi Sankyo RD Novare and DNDi are pleased to announce the financial support of the Japan Global Health Innovative Technology Fund to their new collaboration on natural products.
Geneva / Brentford / Dundee – 27 March 2018
The not-for-profit research and development organization Drugs for Neglected Diseases initiative (DNDi) will collaborate with GlaxoSmithKline (GSK), and the University of Dundee Drug Discovery Unit (DDU), in a bid to discover new pre-clinical drug candidates targeting two parasitic neglected tropical diseases (NTDs), leishmaniasis and Chagas disease.
by Diniz LDF, Mazzeti AL, Caldas IS, Ribeiro I, Bahia MT.
Antimicrobial Agents and Chemotherapy, March 2018
ABC Agencia [8 March 2018]
“Reclaman detener transmisión madre-hijo de Chagas para controlar enfermedad” – “They claim to stop Chagas’ mother-child transmission to control the disease”
El País [20 February 2018]
“Chagas, enfermedad silenciosa que aqueja al pueblo tarijeño” – “Chagas, a silent disease that afflicts the people of Tarija”
7th Edition: Precision Global Health in the Digital Age
10-12 April 2018
Bernard Pécoul, Executive Director – plenary talk on emerging infectious diseases crisis
Digas Ngolo, Investigator Coordinator, DNDi Africa – parallel session on ehealth
8 March 2018
Sergio Sosa-Estani, Head of Chagas, DNDi Latin America – presentation about control programmes for congenital Chagas disease
Michel Lotrowska, Acting Regional Director, DNDi Latin America – participation in the annual meeting Chagas coalition
by Torrico F, Gascon J, Ortiz L, Alonso-Vega C, Pinazo MJ, Schijman A, Almeida IC, Alves F, Strub-Wourgaft N, Ribeiro I.
The Lancet Infectious Diseases, January 2018
Le Quotidien du Médecin [16 January 2018]
“Après 40 ans sans avancée, les premiers pas d’un nouveau traitement de la maladie de Chagas chronique” – “After 40 years without advance, the first steps of a new treatment for chronic Chagas disease”
1-4 March 2018
Buenos Aires, Argentina
Sergio Sosa-Estani, Head of Chagas, DNDi Latin America – presentation on Chagas disease
Byron Arana, Head of Cutaneous Leishmaniasis, DNDi – parallel symposium on cutaneous leishmaniasis
Graciela Diap, Paediatric HIV/HCV, DNDi, and Francisco Viegas Neves da Silva, Regional Policy Advocacy Consultant, DNDi Latin America – parallel symposium on hepatitis C
14-16 February 2018
Sergio Sosa-Estani, Head of Chagas, DNDi Latin America – presentation on the progress on diagnostics and treatments for Chagas disease
by Mazzeti AL, Diniz LDF, Gonçalves KR, Nascimento AFS, Spósito PAF, Mosqueira VCF, Machado-Coelho GLL, Ribeiro I, Bahia MT.
Biochemical Pharmacology, January 2018